135 related articles for article (PubMed ID: 37248699)
1. Adjustment of octreotide dose given via insulin pump based on continuous glucose monitoring (CGM) in a child with congenital hyperinsulinism.
Tiberi V; Cherubini V; Iannilli A; Gasparini F; Marino M
J Pediatr Endocrinol Metab; 2023 Aug; 36(8):803-807. PubMed ID: 37248699
[TBL] [Abstract][Full Text] [Related]
2. Nifedipine in Congenital Hyperinsulinism - A Case Report.
Khawash P; Hussain K; Flanagan SE; Chatterjee S; Basak D
J Clin Res Pediatr Endocrinol; 2015 Jun; 7(2):151-4. PubMed ID: 26316440
[TBL] [Abstract][Full Text] [Related]
3. Conservatively treated Congenital Hyperinsulinism (CHI) due to K-ATP channel gene mutations: reducing severity over time.
Salomon-Estebanez M; Flanagan SE; Ellard S; Rigby L; Bowden L; Mohamed Z; Nicholson J; Skae M; Hall C; Craigie R; Padidela R; Murphy N; Randell T; Cosgrove KE; Dunne MJ; Banerjee I
Orphanet J Rare Dis; 2016 Dec; 11(1):163. PubMed ID: 27908292
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of octreotide for the treatment of congenital hyperinsulinism: a prospective, open-label clinical trial and an observational study in Japan using a nationwide registry.
Hosokawa Y; Kawakita R; Yokoya S; Ogata T; Ozono K; Arisaka O; Hasegawa Y; Kusuda S; Masue M; Nishibori H; Sairenchi T; Yorifuji T
Endocr J; 2017 Sep; 64(9):867-880. PubMed ID: 28701683
[TBL] [Abstract][Full Text] [Related]
5. Characterization of diabetes following pancreatic surgery in patients with congenital hyperinsulinism.
Welters A; Meissner T; Grulich-Henn J; Fröhlich-Reiterer E; Warncke K; Mohnike K; Blankenstein O; Menzel U; Datz N; Bollow E; Holl RW
Orphanet J Rare Dis; 2018 Dec; 13(1):230. PubMed ID: 30577875
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of long-term, continuous subcutaneous octreotide infusion for patients with different subtypes of KATP-channel hyperinsulinism.
Yorifuji T; Kawakita R; Hosokawa Y; Fujimaru R; Matsubara K; Aizu K; Suzuki S; Nagasaka H; Nishibori H; Masue M
Clin Endocrinol (Oxf); 2013 Jun; 78(6):891-7. PubMed ID: 23067144
[TBL] [Abstract][Full Text] [Related]
7. Monoallelic ABCC8 mutations are a common cause of diazoxide-unresponsive diffuse form of congenital hyperinsulinism.
Saint-Martin C; Zhou Q; Martin GM; Vaury C; Leroy G; Arnoux JB; de Lonlay P; Shyng SL; Bellanné-Chantelot C
Clin Genet; 2015 May; 87(5):448-54. PubMed ID: 24814349
[TBL] [Abstract][Full Text] [Related]
8. Octreotide-LAR is a Useful Alternative for the Management of Diazoxide-Responsive Congenital Hyperinsulinism.
Karlekar MP; Sarathi V; Arya S; Flanagan SE; Patil V; Lila A; Shah N; Bandgar T
Horm Metab Res; 2021 Nov; 53(11):723-729. PubMed ID: 34740273
[TBL] [Abstract][Full Text] [Related]
9. [Continuous subcutaneous infusion of somatostatin analogues in the treatment of congenital hyperinsulinism].
Melikyan MA; Gubaeva DN; Kareva MA
Probl Endokrinol (Mosk); 2020 Sep; 66(3):81-87. PubMed ID: 33351342
[TBL] [Abstract][Full Text] [Related]
10. Congenital hyperinsulinism due to compound heterozygous mutations in ABCC8 responsive to diazoxide therapy.
Taylor-Miller T; Houghton J; Munyard P; Kumar Y; Puvirajasinghe C; Giri D
J Pediatr Endocrinol Metab; 2020 May; 33(5):671-674. PubMed ID: 32267248
[TBL] [Abstract][Full Text] [Related]
11. Octreotide-related exocrine pancreatic insufficiency (EPI) in congenital hyperinsulinism.
Ros-Pérez P; Golmayo L; Cilleruelo ML; Gutiérrez C; Celaya P; Lacámara N; Martínez-Badás I; Güemes M; Argente J
J Pediatr Endocrinol Metab; 2020 Jul; 33(7):947-950. PubMed ID: 32634108
[TBL] [Abstract][Full Text] [Related]
12. A Newborn with Congenital Hyperinsulinism.
Du Y; Ju R; Xi Y; Gou P
Fetal Pediatr Pathol; 2019 Oct; 38(5):406-411. PubMed ID: 31002010
[No Abstract] [Full Text] [Related]
13. The effectiveness of continuous subcutaneous insulin pumps with continuous glucose monitoring in outpatient adolescents with type 1 diabetes: A systematic review.
Matsuda E; Brennan P
JBI Libr Syst Rev; 2012; 10(42 Suppl):1-10. PubMed ID: 27820140
[TBL] [Abstract][Full Text] [Related]
14. Novel mutation c.597_598dup in exon 5 of ABCC8 gene causing congenital hyperinsulinism.
Jindal R; Ahmad A; Siddiqui MA; Kochar IS; Wangnoo SK
Diabetes Metab Syndr; 2014; 8(1):45-7. PubMed ID: 24661758
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Nifedipine Therapy in Hyperinsulinemic Hypoglycemia due to Mutations in the ABCC8 Gene.
Güemes M; Shah P; Silvera S; Morgan K; Gilbert C; Hinchey L; Hussain K
J Clin Endocrinol Metab; 2017 Mar; 102(3):822-830. PubMed ID: 27898257
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus in the treatment of three infants with diffuse congenital hyperinsulinism.
Al-Balwi R; Al-Atawi M; Al-Otaibi A; Babiker O; Al-Mutair A
J Pediatr Endocrinol Metab; 2017 Aug; 30(9):1013-1017. PubMed ID: 28787272
[TBL] [Abstract][Full Text] [Related]
17. A combination of nifedipine and octreotide treatment in an hyperinsulinemic hypoglycemic infant.
Durmaz E; Flanagan SE; Parlak M; Ellard S; Akcurin S; Bircan I
J Clin Res Pediatr Endocrinol; 2014; 6(2):119-21. PubMed ID: 24932607
[TBL] [Abstract][Full Text] [Related]
18. The Use of a Long-Acting Somatostatin Analogue (Lanreotide) in Three Children with Focal Forms of Congenital Hyperinsulinaemic Hypoglycaemia.
Dastamani A; Güemes M; Pitfield C; Morgan K; Rajab M; Rottenburger C; Bomanji J; De Coppi P; Dattani M; Shah P
Horm Res Paediatr; 2019; 91(1):56-61. PubMed ID: 30114684
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus in infants with congenital hyperinsulinism (CHI) - a single-centre experience.
Panigrahy N; Chirla DK; Bagga N; Gunda RK; Sukhija B; Reddy L
Eur J Pediatr; 2022 Jan; 181(1):407-412. PubMed ID: 34304300
[TBL] [Abstract][Full Text] [Related]
20. Characterization of ABCC8 and KCNJ11 gene mutations and phenotypes in Korean patients with congenital hyperinsulinism.
Park SE; Flanagan SE; Hussain K; Ellard S; Shin CH; Yang SW
Eur J Endocrinol; 2011 Jun; 164(6):919-26. PubMed ID: 21422196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
